Clinical research

#Automation / robotics #Biobanking #Biorepository #Clinical research #Life sciences #Research

Brooks Automation and Cleveland Clinic biobank collaboration 

Brooks Automation and Cleveland Clinic have opened a 22,000-square-foot biospecimen sample management and repository facility on Cleveland Clinic’s main campus.   The biorepository is managed by Azenta Life Sciences, Brooks’ recently re-branded life sciences division, and includes ultra-cold and cryogenic storage for researchers at Cleveland Clinic and other institutions. The… Read More

#News

#Blood bank #Clinical research

Refrigerators provide enhanced functionality for secure blood storage

Clinical researchers can now benefit from a new range of fully compliant and sustainable refrigerators designed specifically for the cold storage of blood and blood-related products and samples.   The Thermo Scientific TSB Series of blood bank refrigerators are built to comply with the Class IIa regulation 93/42/CE. Factory presets… Read More

#News

#Clinical research #Parkinson's

New Parkinson’s study investigates treatment of non-motor symptoms  

The design for two new trials investigating opicapone in the treatment of non-motor symptoms in patients with motor fluctuations in Parkinson’s disease (PD) have been presented at the International Parkinson and Movement Disorder Society’s Virtual Congress (MDS Virtual Congress 2021). Usually associated with motor symptoms, opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved in Europe… Read More

#News

#Biopharmaceuticals #Clinical research #Drug development #Therapeutics

Antibody-mediated therapies: meeting the challenges in R&D

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by… Read More

#Editor's Choice #Exclusive Content #News

Human brain
#Biomarkers #Clinical research #Schizophrenia #Therapeutics

Study to overcome biological heterogeneity challenges by 2022 

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over… Read More

#News

#Biotherapeutics #Clinical research #Microbiome #Therapeutics

Report reveals the potential of microbiome-targeting therapeutics

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More

#Market Reports #News #Trends & Analysis

#Clinical research #Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Positive interim Phase II results for GSK Medicago Covid-19 vaccine

Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More

#Covid-19 #News

#Cell and gene therapy #Clinical research #Drug development

Update on gene therapy trial where patient suffered loss of vision

Adverum Biotechnologies has announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its Infinity clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomisation in one patient treated with a single intravitreal… Read More

#News

#Awards #Clinical research

Veramed achieves Best Companies accreditation

Clinical Research Organisation (CRO) Veramed has gained a three-star rating by Best Companies, showing ‘world class’ levels of employee engagement. Veramed achieved its rating due to its commitment to employee development, wellbeing and mental health programmes, a flexible work-life balance and charity initiatives to promote employee satisfaction and engagement. CEO… Read More

#News